Sunday, November 15, 2026

Peer-Reviewed Clinical Evidence Platform

The research that matters, without the jargon.

Peer-reviewed breakthroughs in plain English alongside verified outcomes, evidence grades, and clinical study details for everyone from everyday readers to medical students.

ClearMed Editorial Digest500 briefings across 12 specialties121 Phase III & clinical practice

Indexed from PubMed, NEJM, The Lancet, JAMA, Nature MedicineSaved Library

Health Hubs:

Stage: Evidence:

Showing 8 briefings matching “inflammation”

Reset all filters

Pulmonology

Pulmonology Clinical Briefings

Peer-Reviewed Clinical Digests · Verified Scientific Media

PULMONOLOGY · PHASE III

Longitudinal change in FEV 1 in adults with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor in France: a prospective observational study

These results suggest that about a third of adults with cystic fibrosis (tissue scarring) who are treated with ETI had a persistent decline in ppFEV 1 . These data emphasise the importance of regular ppFEV 1 monitoring and highlight the need to improve current therapeutic strategies to prevent ppFEV 1 decline.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readThe Lancet Respiratory MedicineNov 11, 2026

PULMONOLOGY · REAL-WORLD COHORT

Associations between temperatures, extreme temperature events, and onset of acute exacerbations of COPD: a time-stratified case-crossover study in China

Lower temperature and extreme cold events, particularly CCS, were associated with AECOPD onset. Symptom-onset timing may better capture temperature-related associations than admission timing.

4/5 Strong Trial

Evidence Meter · 4/5

Strong Clinical Evidence

Tested directly in patients through a prospective clinical trial or large multicenter human cohort.

1 min readChestNov 11, 2026

PULMONOLOGY · REAL-WORLD COHORT

Systemic Inflammation in Bronchiectasis: Data from the EMBARC-BRIDGE Study

Bronchiectasis is associated with a systemic neutrophil and endothelial (blood-vessel lining) inflammatory signature linked to disease severity and risk of severe exacerbations, alongside altered but functionally-responsive circulating neutrophils. Neutrophilic inflammation in the airways is associated with exacerbation risk in patients with bronchiectasis.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readAmerican Journal of Respiratory and Critical Care MedicineNov 7, 2026

PULMONOLOGY · REAL-WORLD COHORT

The Impact of Undernutrition on Post-Tuberculosis Lung-Function: A Prospective Cohort Study

Undernutrition before and at treatment initiation is a potentially modifiable determinant of post-treatment lung impairment, with systemic inflammation mediating part of the effect. Nutritional assessment belongs in routine tuberculosis care, and nutritional support should be tested to prevent lung-function impairment in tuberculosis survivors.

4/5 Strong Trial

Evidence Meter · 4/5

Strong Clinical Evidence

Tested directly in patients through a prospective clinical trial or large multicenter human cohort.

1 min readChestNov 5, 2026

PULMONOLOGY · RANDOMIZED CLINICAL TRIAL

Dupilumab is associated with improved lung functions in patients with COPD and type 2 inflammation: a post hoc analysis of the BOREAS and NOTUS trials

Dupilumab treatment resulted in early and sustained improvements across multiple spirometric lung function parameters in patients with COPD and type 2 inflammation. To perform in-depth analyses of the efficacy (real-world effectiveness in the trial) of dupilumab on lung function parameters in patients with COPD and type 2 inflammation.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readAmerican Journal of Respiratory and Critical Care MedicineOct 30, 2026

PULMONOLOGY · CLINICAL PRACTICE

Long-term safety and efficacy of twice-yearly depemokimab in type 2 asthma with an eosinophilic phenotype: 2-year integrated analysis of the phase 3a SWIFT-1 and SWIFT-2 studies and AGILE open-label extension

Twice-yearly depemokimab was well tolerated and demonstrated sustained efficacy (real-world effectiveness in the trial) over the 2-year SWIFT and AGILE period, supporting its long-term therapeutic benefit and safety profile. Depemokimab is the first ultra-long-acting biologic, with enhanced interleukin-5 binding affinity, high potency, and extended half-life, enabling twice-yearly dosing.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readThe Lancet Respiratory MedicineOct 29, 2026

PULMONOLOGY · REAL-WORLD COHORT

2026 Global Initiative for Asthma (GINA) Strategy Report: Executive Summary and Key Changes

GINA integrates evidence-based management with shared decision-making, self-management education, implementation, and global advocacy to reduce preventable asthma morbidity and risk of death. For difficult-to-treat and severe asthma, GINA provides structured guidance, emphasizing diagnostic verification, optimization of modifiable factors, inflammatory phenotyping, biologic therapy selection, and (as for all patients) systemic corticosteroid stewardship.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readAmerican Journal of Respiratory and Critical Care MedicineOct 8, 2026

PULMONOLOGY · REAL-WORLD COHORT

Nodular Fasciitis of the Lung: A Novel Entity

This case highlights the importance of careful evaluation of pseudotumors of the lung and specialist multidisciplinary team assessment. Pulmonary tumors in young individuals may differ in their causes from older individuals, with a more broad and potentially benign process in the differential diagnosis.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readChestOct 6, 2026

Interactive Fact Check